Study Shows Improvement in Pleural Mesothelioma Patients Treated with Cisplatin Plus Raltitrexed

Pleural mesothelioma patients treated with both cisplatin and raltitrexed may survive longer than patients who receive cisplatin alone, according to a recent study conducted in Europe and Canada (J Clin Oncol. 2005 Oct 1; 23(28): 68819). Raltitrexed (Tomudex) works by interfering with the ability of tumor cells to multiply and make deoxyribonucleic acid or DNA. Cisplatin is a traditional chemotherapy drug.

Two hundred fifty pleural mesothelioma patients took part in a clinical trial to determine the safety and effectiveness of raltitrexed. One hundred twentyfour patients took cisplatin and the rest took cisplatin plus raltitrexed. Most were men with an average age of 58 who had not received other chemotherapy treatments.

The raltitrexed study was a phase III clinical trial, as defined by the European Organization for Research and Treatment of Cancer. A phase III trial compares a new cancer treatment with a standard treatment, and requires a large number of participants. It follows a phase II clinical trial, which is concerned with the safety of a new treatment and how to administer it, and a basic phase I clinical trial, which tests the drugs effectiveness on a small number of patients.

Survival Increased in Patients Treated with Raltitrexed

The researchers looked at survival, progression of pleural mesothelioma, safety, tumor response rates, and the patients quality of life. They found the following:

Fortysix percent of pleural mesothelioma patients in the cisplatin/raltitrexed group survived at least one year, compared to 40% of those in the cisplatin group.

The average survival was 11.4 months for patients in the cisplatin/raltitrexed group, but only 8.8 months for patients in the cisplatin group.

Twentyfour percent of patients treated with cisplatin/raltitrexed had a positive response against pleural mesothelioma compared to 14% of patients treated with cisplatin.

The overall quality of life was about the same in the cisplatin group as compared to the cisplatin/raltitrexed group.

A small number of patients in both the cisplatin and cisplatin/raltitrexed groups developed low white blood cell counts (neutropenia). Other side effects included fatigue, nausea, and vomiting, which were more common in the combined drug group.

Raltitrexed Is Related to the Pleural Mesothelioma Drug Alimta

Raltitrexed is in the class of chemotherapy drugs called antifolates. It blocks the production of thymidylate synthase, which in turn decreases the mesothelioma cells ability to make DNA, the basic genetic material involved in cell reproduction. It is registered in Europe for the treatment of advanced colorectal cancer.

Raltitrexed is closely related to pemetrexed (Alimta), another antifolate. Currently, pemetrexed/cisplatin is the only chemotherapy drug combination that the US Food and Drug Administration has approved to treat pleural mesothelioma.

The authors of the raltitrexed study concluded that combining cisplatin with an antifolate such as raltitrexed or pemetrexed is more helpful in treating pleural mesothelioma than using cisplatin alone. They also felt that cisplatin plus raltitrexed did not have a harmful effect on the patients quality of life.

More information: http://www.mesothelioma-info-asbestos.com/

Latest Mesothelioma Research: Combination Improves Survival
The following mesothelioma research findings were reported in a recent issue of the Journal of Clinical Oncology. Mesothelioma researchers have report...

Malignant Mesothelioma Research
Malignant mesotheliomas are highly aggressive cancers, usually linked to asbestos exposure. Most patients survive approximately one year after diagno...

Alimta-Cisplatin Regimen for Malignant Mesothelioma
Chemotherapy is the use of drugs to treat cancer patients. These drugs can be used to reduce the size of tumors prior to surgery, or as the primary tr...

New Mesothelioma Treatment Research Shows Promise
New mesothelioma treatment research to determine if chemotherapy before surgery and radiation can prevent mesothelioma recurrence could provide a majo...

Malignant Pleural Mesothelioma Survival Rate
Malignant Pleural Mesothelioma is a lethal cancer that starts in the lining of the lungs. The main cause is believed to be unprotected contact with as...

The Facts About Pleural Mesothelioma
Pleural mesothelioma is the most common form of mesothelioma by far and accounts for 75% of all mesothelioma cases. Pleural mesothelioma affects the ...

Pleural Asbestosis - Treatment for Mesothelioma Symptoms
An October 2005 report states that a new method that assists diagnosis of pleural mesothelioma is to measure the presence of osteopontin in blood. ...

Diffuse Malignant Pleural Mesothelioma
Diffuse malignant pleural mesothelioma, or DMM, is a rare but highly aggressive type of cancer. It occurs in the thin layer of tissue, the pleura, li...

Mesothelioma Treatment Options
Mesothelioma is very similar to other cancers in respect to treatment. Mesothelioma patients have three treatment options available to them: chemother...

High Dose Radiation Therapy Improves Survival in Patients with Mesothelioma
Mesothelioma is very rare disease, but once it strikes, death becomes inevitable. This lethal disease is caused due to exposure to asbestos. A recent ...

Pleural Mesothelioma - A Quick Look
Pleural mesothelioma is one of several types of cancer linked to asbestos exposure. It is caused by asbestos fibers being ingested into the lungs and...

Mesothelioma Treatment - Chemotherapy
Mesothelioma is a cancerous disease that affects the serous linings of various internal organs in the human body. Among them, the lungs, heart and the...

Peritoneal Mesothelioma Survival Rates
Peritoneal Mesothelioma is a cancer of the abdomen lining caused due to prolonged exposure to asbestos. Thousands of lawsuits are handled every year d...

Mesothelioma Pleural Symptoms
Mesothelioma Pleural or Pleural Mesothelioma is generally a severe form of cancer that affects the membrane lining in the thoracic cavity. There are a...

Pleural Mesothelioma - The Truth and Facts About Pleural Meseothelioma
Pleural Mesothelioma represents for about 75% of all Mesothelioma cases and. The main cause for this type of cancer is the inhalation of asbestos fibe...

This entry was posted on Tuesday, May 13th, 2008 at 10:15 am and is filed under Mesothelioma Cancer . You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.